In line with Nature Research's publishing standards, we run quality checks on competing interests, ethics approval, and more when you submit your manuscript. Learn more about our editorial process in this brief video. https://go.nature.com/SrepEPV | Scientific Reports

ctDNA: Personalising Cancer Treatment Next generation sequencing of circulating tumour DNA identifies clinically-actionable mutations (in 71% of patients), 177 ctDNA-unique abnormalities (particularly in Chinese lung cancer patients), and drug resistant mutations. This form of mutation profiling could help guide individual cancer treatment, drug and therapy decisions. Read more here: https://go.nature.com/2NHXY8M | Scientific Reports